BioSpace News Archive

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported initial data from the monotherapy dose-escalation portion of its Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Vor Bio announced that, effective as of October 30, 2023, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 50,000 shares of Vor Bio’s common stock and restricted stock units representing the right to receive an aggregate of 75,000 shares of Vor Bio’s common stock to four newly hired employees.

IceCure Medical Ltd. announced that it has received a written notice from Nasdaq Stock Market LLC indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share.

Blueprint Medicines Corporation, announced that, effective November 1, 2023, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 5,034 shares of its common stock and an aggregate of 2,517 restricted stock units to three new employees under Blueprint Medicines’ 2020 Inducement Plan.

Syndax Pharmaceuticals announced that on November 1, 2023 the Company granted inducement awards to purchase up to 169,600 shares of common stock to ten new employees under the Company’s 2023 Inducement Plan.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, announced the grant of inducement awards to one new employee.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 50,000 shares of its common stock with an exercise price of $0.77 per share, the closing price of Kezar’s common stock on November 1, 2023, the grant date of the award.

Inozyme Pharma, Inc. announced that it granted stock options to new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in November.